Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 988 across all filing types
Latest filing 2026-02-20 Annual Report
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
20-F - TELIX PHARMACEUTICALS LTD (0002007191) (Filer)
Annual Report FY 2025
2026-02-20 English
Change in substantial holding 37 pages 2.4MB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 filed under the Corporations Act 2001, Section 671B, titled 'Notice of change of interests of substantial holder.' It details changes in voting power and relevant interests of JPMorgan Chase & Co. and its affiliates in Telix Pharmaceuticals Ltd. The form includes specifics on securities transactions, changes in association, and addresses of related entities. This type of filing is a notification of changes in significant share ownership levels, which corresponds to a Major Shareholding Notification. The document is lengthy and contains detailed transaction data, consistent with a substantial holder notice rather than a simple announcement or certification. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2026-02-19 English
Appendix 4E and 2025 Annual Report 374 pages 3.7MB
Regulatory Filings
2026-02-19 English
2025 Full Year Results Announcement 5 pages 156.0KB
Earnings Release Classification · 95% confidence The document is an ASX announcement dated February 20, 2026, presenting the full year financial results for the fiscal year ended December 31, 2025. It includes detailed financial data such as revenue, EBITDA, operating profit, and segment performance, as well as guidance for the next fiscal year. The document also contains executive commentary and references to an upcoming investor call and webcast. The length is substantial (15,000 characters), and it contains comprehensive financial results and analysis, not just a brief announcement or a link to a report. This matches the characteristics of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights. It is not a full Annual Report (10-K) or Interim Report (IR) because it is a summary announcement of the fiscal year results, typical of an earnings release. Therefore, the correct classification is ER with high confidence.
2026-02-19 English
2025 Full Year Results Presentation 32 pages 2.7MB
Annual Report Classification · 95% confidence The document is a detailed presentation containing extensive financial data, strategic priorities, CEO remarks, and forward-looking statements. It includes full financial metrics for the fiscal year 2025, revenue figures, EBITDA, R&D investments, and other substantive financial information. The presence of detailed financial performance data, strategic outlook, and management commentary indicates this is a comprehensive financial report rather than a brief announcement or presentation. The document references the Annual Report on Form 20-F but is not itself a certification or announcement of a report. Given the depth and breadth of financial and operational data, this document fits the definition of an Annual Report (10-K equivalent for non-US companies).
2026-02-19 English
Appendix 4G and 2025 Corporate Governance Statement 35 pages 1.4MB
Regulatory Filings
2026-02-19 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.